AstraZeneca (NYSE:AZN) will collaborate with contract research services and advanced analytics provider IQVIA (NYSE:IQV) under the U.S. government’s Operation Warp Speed to accelerate the delivery of U.S. clinical trials evaluating COVID-19 vaccine candidate AZD1222.
Enrollment will launch this summer in an expansive subject study leveraging IQV’s Virtual Trial solutions including Study Hub.
Financial terms are not disclosed.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.